Research programme: inflammatory disease therapeutics - Array BioPharma/Celgene Corporation
Latest Information Update: 31 Jul 2013
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Celgene Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 29 Jul 2013 Preclinical trials in Inflammation in USA (unspecified route)